soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm align more closely with attained dose than achieved weight loss NEJM Editorial Fellow Harleen Marwah,

Does stopping semaglutide reduce anesthesia risks

doi: 10.1016/j.cgh.2024.03.013

As more people look for affordable treatment options, the demand for a semaglutide generic reusable pen is increasing very quickly

See all articles Overview Semaglutide and tirzepatide are peptides similar to two hormones produced by the digestive system, namely glucagon-like peptide-1 (GLP-1) and glucosedependent insulinotropic polypeptide (GIP)

You can make finer dose adjustments (like stepping from 0.5 mg to 0.75 mg instead of jumping straight to 1.0 mg) and you can use split dosing strategies that pre-filled pens do not allow

doi: 10.2337/db20-0153